The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients,...

HC restrained Glenmark from making, selling, advertising, distributing or exporting its anti-diabetes drugs Zita and Zita-Met.

Earlier, in an interim order, a division bench of the high Court had restrained Glenmark from making or selling its drug, used for treatmen...

Glenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal from the US Food and Drug Administration (US...

A new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%.

The apex court allowed Glenmark Pharmaceuticals to continue selling existing stock of its anti-diabetes drugs Zita and Zita-Met in the mark...

Shares of Glenmark Pharmaceuticals lost 4.51 per cent after high court barred it from making, marketing or selling its anti-diabetes medici...

Glenmark slipped 5% in trade on Monday, after Delhi high court restrained the company from manufacturing and marketing anti-diabetes drug.

The company has raked in Rs 16 crore in just 8 months since drug was launched.

The Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.

Justice S Ravindra Bhat and SK Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging the sing...

The American drug major is involved in a patent row with Glenmark which has recently come out with the two medicines in alleged violation o...

A bench of justices Sanjay Kishan Kaul and Indermeet Kaur took the plea of US pharma major on record and posted it for hearing before anoth...

MSD has filed an appeal before the Delhi HC challenging its single bench order refusing to grant interim relief to it on a patent row again...

Delhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.

The court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...

The development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-...